Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEco Animal Regulatory News (EAH)

Share Price Information for Eco Animal (EAH)

Share Price is delayed by 15 minutes
Get Live Data
92.00    0.00 (0.00%)
Bid:
91.00
Ask:
93.00
Spread: 2.00 (2.198%)
Market Cap: £61.72m
EAH Live PriceLast checked at - London Stock Exchange

Intraday Eco Animal Share Chart

Directorate change

1 Dec 2017 07:00

1 December 2017

ECO Animal Health Group plc

(AIM: EAH)

Board changes

ECO Animal Health Group plc (β€œECO”), a leader in the development, registration and marketing of pharmaceutical products for animals, is pleased to announce that effective today Dr Andrew Alfred Jones PhD, BSc (Hons) has joined the board as an independent non-executive director.

Dr Andrew A. Jones (aged 57) has over 32 years’ experience in the global life sciences industry and has more recently held the positions of non-executive chairman of Downland Marketing Limited, a distribution franchise group supplying animal health and nutrition products to grassland animal farmers and non-executive director of Zedlock Limited, which designs and sells patented high security locks to the agricultural and industrial sectors. Andrew started his career and spent his first 15 years with Syngenta (formerly Zeneca Agrochemicals) in various managerial roles.

In accordance with corporate governance best practice, with effect from 1 December 2017, David Danson is retiring from the board after nine years of service as a non-executive director and Peter Lawrence, currently executive chairman, will become non-executive chairman with effect from 1 January 2018.

Peter Lawrence, executive chairman of ECO, commented β€œWe are delighted that Andrew will be joining the board and bringing to us his vast global animal health and corporate governance experience. His knowledge will complement our strong board following David Danson’s retirement. We thank David for his invaluable contributions over many years.”

Further information disclosable under Schedule Two paragraph (g) of the AIM Rules for Companies:

Dr Andrew A. Jones has held directorships in the following companies in the last 5 years and continues to do so.

Trioza Limited

Downland Marketing Limited

Zedlock Limited

Save as disclosed, there is no other information to be disclosed in respect of Dr Andrew A. Jones under Schedule Two paragraph (g) of the AIM Rules for Companies.

Contacts:

ECO Animal Health Group plc

Peter Lawrence 020 8336 6190
Marc Loomes 020 8447 6906
Spiro Financial
Anthony Spiro 020 8336 6196
Peel Hunt LLP (Nominated Adviser and Joint Broker)
Dan Webster

George Sellar

020 7418 8900
N+1 Singer (Joint Broker)
Mark Taylor

Brough Ransom

020 7496 3000

LEI: 2138009XN9DJ3YP70B55

Classification: 3.1 Additional regulated information required to be disclosed under the laws of a Member State

View source version on businesswire.com: http://www.businesswire.com/news/home/20171130005538/en/

Copyright Business Wire 2017

Date   Source Headline
4th Jun 20267:00 amRNSRenewal of revolving credit facility
14th Apr 20267:00 amRNSAppointment of Head of Business Development
31st Mar 20267:00 amRNSBoard Change
19th Mar 20267:00 amRNSFull Year Trading Update
11th Mar 20267:00 amRNSECOVAXXIN® MG favourable USDA safety assessment
11th Mar 20267:00 amRNSECOVAXXIN®?MG favourable USDA safety assessment
5th Mar 20264:19 pmRNSBlock Listing Return
26th Feb 20267:00 amRNSEU launch plans for ECOVAXXIN® MS
19th Jan 20261:50 pmRNSHolding(s) in Company
22nd Dec 20257:00 amRNSECOVAXXIN® MS EU marketing authorisation granted
22nd Dec 20257:00 amRNSECOVAXXIN® MS EU marketing authorisation granted
18th Dec 20257:00 amRNSExercise of Share Options by Director
9th Dec 20255:57 pmRNSHolding(s) in Company
4th Dec 20252:10 pmRNSDirector/PDMR Shareholding
1st Dec 20257:00 amRNSResults for the six months ended 30 September 2025
20th Nov 20259:47 amRNSReplacement: Notice of Results
20th Nov 20257:00 amRNSNotice of Results
10th Nov 20257:00 amRNSEMA Positive Opinion Received for ECOVAXXIN® MS
1st Oct 20257:00 amRNS-RHead of Global R&D
25th Sep 20253:15 pmRNSResult of AGM
25th Sep 20257:00 amRNSAGM Trading Update and Notice of Interim Results
1st Sep 20257:00 amRNSAppointment of Joint Broker
29th Aug 20257:00 amRNSShare Awards to Executive Directors
28th Aug 20257:48 amRNSPosting of Annual Report and Notice of AGM
21st Aug 202512:29 pmRNSResult of General Meeting
13th Aug 20257:00 amRNSBlock Listing Return
6th Aug 20255:09 pmRNSHolding(s) in Company
17th Jul 20257:00 amRNSHolding(s) in Company
15th Jul 20251:00 pmRNSDirector/PDMR Shareholding
14th Jul 20257:00 amRNSResults for the year ended 31 March 2025
8th Jul 20254:10 pmRNSNotice of General Meeting and Notice of Results
2nd May 20257:00 amRNSHolding(s) in Company
28th Apr 20257:00 amRNSDirector/PDMR Shareholding
24th Apr 20257:00 amRNSTrading Update
13th Mar 20257:00 amRNSR&D Day
3rd Mar 20257:00 amRNSSubmission of Marketing Authorisation Application
24th Feb 20254:08 pmRNSHolding(s) in Company
19th Feb 20257:00 amRNSDisposal of non-core assets
18th Feb 20257:00 amRNSBlock listing Interim Review
13th Feb 20257:00 amRNSNotice of R&D Day
31st Jan 20257:00 amRNSBoard Changes
20th Dec 20247:00 amRNSHolding(s) in Company
16th Dec 20247:00 amRNSHolding(s) in Company
2nd Dec 202412:30 pmRNSShare Purchase by Executive Director
28th Nov 20247:00 amRNSResults for the Six Months Ended 30 September 2024
28th Oct 202412:57 pmRNSShare Awards to Executive Directors
22nd Oct 202411:00 amRNSEBT Share Purchase
21st Oct 20247:00 amRNSEBT Share Purchase
14th Oct 202411:07 amRNSEBT Share Purchase
9th Oct 20247:00 amRNSIssue of Equity and TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.